Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Sepsis-associated acute kidney injury (SA-AKI) is frequent in intensive care and carries high morbidity and mortality. Excess circulating free iron contributes to oxidative stress, inflammation, and tubular injury during acute kidney injury (AKI) and sepsis. We evaluated the feasibility, tolerance, and iron-chelating efficacy of a novel dialysate containing the macromolecular chelator MEX-CD1, designed to extract free iron without systemic exposure.
The project comprised two consecutive phases.
(1) Preclinical study (porcine sepsis model): Septic AKI was induced by peritonitis in 3 pigs. Animals received continuous venovenous hemodialysis (CVVHD) for 24 h with dialysate enriched with MEX-CD1. Hemodynamics, diuresis, serum creatinin, electrolytes, and Metallic trace element (MTE) in dialysate were monitored. Such as renal histopathology including Perls, GPX4, and TUNEL staining.
(2) Clinical pilot study (ongoing): A prospective single-centre, randomised, open-label, crossover phase I–II trial in critically ill adults with Sepsis AKI requiring hemodialysis. Fourteen patients will be included. The study will compares a 24 h CVVHD session with standard dialysate and one with MEX-CD1 dialysate. Primary endpoint: iron extraction. Secondary endpoints: iron clearance, oxidative stress (malondialdehyde, MDA), inflammation and Metallic trace element (MTE).
In septic pigs, all animals developed sepsis with fever, hypotension, and acute kidney injury within hours of peritonitis induction, while surviving 48 h under hemodynamic support. Dialysis was feasible but limited by membrane clotting. Histology confirmed acute tubular necrosis with GPX4-positive and TUNEL-negative staining, consistent with ferroptosis-like injury. Iron accumulation was minimal on Perls staining. The iron-chelating dialysate (MEX-CD1) removed measurable iron without significant loss of trace elements or hemodynamic instability, supporting the feasibility and biological relevance of this therapeutic approach.
Human study is ongoing to consolidate tolerance and efficacy data.
This porcine model of sepsis-induced acute kidney injury demonstrated the feasibility and safety of extracorporeal iron removal using MEX-CD1. These findings provide a strong translational basis for ongoing first-in-human studies. Together, the preclinical and clinical investigations aim to establish targeted labile iron extraction with MEX-CD1 as a novel therapeutic approach for sepsis-associated acute kidney injury (SA-AKI).
